ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL1477
CHEMBL1477
Compound Name CERIVASTATIN
ChEMBL Synonyms BAY W 6228 | BAYCOL | Lipobay | CERIVASTATIN | Baycol | CERIVASTATIN SODIUM
Max Phase 4 (Approved)
Withdrawn Yes
Trade Names BAYCOL
Molecular Formula C26H34FNO5

Additional synonyms for CHEMBL1477 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES COCc1c(nc(C(C)C)c(\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)c1c2ccc(F) ...
Download SMILES
Standard InChI InChI=1S/C26H34FNO5/c1-15(2)25-21(11-10-19(29)12-20(30)13-23 ...
Download InChI
Standard InChI Key SEERZIQQUAZTOL-ANMDKAQQSA-N

Sources

  • AstraZeneca Deposited Data
  • British National Formulary
  • DrugMatrix
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • TP-search Transporter Database
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification
  • Withdrawn Drugs

Alternate Forms of Compound in ChEMBL


CHEMBL1477

Molecule Features

CHEMBL1477 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Single Stereoisomer Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:N Availability Type:Withdrawn

Withdrawal Information

Year 2001
Country United States
Reason Rhabdomyolysis _ kidney failure and muscle damage

Mechanism of Action

Mechanism of Action ChEMBL Target References
HMG-CoA reductase inhibitor HMG-CoA reductase ISBN

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
CARDIOVASCULAR DISEASESD002318EFO:0000319CARDIOVASCULAR DISEASE4ATC

Clinical Data

ClinicalTrials.gov CERIVASTATIN
The Cochrane Collaboration CERIVASTATIN

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL1477. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL402 HMG-CoA reductase Homo sapiens 1.000
CHEMBL3247 HMG-CoA reductase Rattus norvegicus 1.000

10uM


ChEMBL_ID Target Name Organism Score
CHEMBL402 HMG-CoA reductase Homo sapiens 1.000
CHEMBL3247 HMG-CoA reductase Rattus norvegicus 1.000

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
459.6 459.2421 4.2 11 99.88 ACID


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
6 3 0 6 3 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
4.24 5.61 3.18 .07 2 33 0.47

Structural Alerts

There are 1 structural alerts for CHEMBL1477. To view alerts please click here.

Compound Cross References

ATC C - CARDIOVASCULAR SYSTEM
C10 - LIPID MODIFYING AGENTS
C10A - LIPID MODIFYING AGENTS, PLAIN
C10AA - HMG CoA reductase inhibitors
C10AA06 - cerivastatin

ChemSpider ChemSpider:SEERZIQQUAZTOL-ANMDKAQQSA-N
PubChem SID: 50111694
Wikipedia Cerivastatin

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL1477



ACToR 145599-86-6
BindingDB 18376
ChEBI 3558
DrugBank DB00439
DrugCentral 577
EPA CompTox Dashboard DTXSID9022786
FDA SRS AM91H2KS67
Guide to Pharmacology 2950
KEGG Ligand C07966
LINCS LSM-43237
Nikkaji J934.489F
PharmGKB PA448897
PubChem 446156
PubChem: Thomson Pharma 14858094 14809054
SureChEMBL SCHEMBL16346
ZINC ZINC000011330186

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/SEERZIQQUAZTOL-ANMDKAQQSA-N spacer
spacer